MAP2K7 and melanoma: The introduction of targeted therapies, including BRAF inhibitors (e.g., vemurafenib (VEM) and dabrafenib) and MEK inhibitors (e.g., trametinib (TRA) and cobimetinib), has marked a significant therapeutic advancement for patients with BRAF-mutated melanoma over the past decade [15,16,17].